List of Excipients in Branded Drug JATENZO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TOLMAR Inc	JATENZO	testosterone undecanoate	69087-158	BORAGE OIL	2026-04-14
TOLMAR Inc	JATENZO	testosterone undecanoate	69087-158	BUTYLATED HYDROXYTOLUENE	2026-04-14
TOLMAR Inc	JATENZO	testosterone undecanoate	69087-158	FD&C YELLOW NO. 6	2026-04-14
TOLMAR Inc	JATENZO	testosterone undecanoate	69087-158	FERRIC OXIDE RED	2026-04-14
TOLMAR Inc	JATENZO	testosterone undecanoate	69087-158	GELATIN	2026-04-14

JATENZO Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

JATENZO is an oral testosterone undecanoate product whose commercial value depends on lipid-based delivery, food-effect management, dose flexibility, and the ability to avoid the compliance burden associated with testosterone injections, patches, gels, and buccal systems. Its excipient strategy is central to absorption and product differentiation, not a secondary formulation issue.

The main commercial opportunities are improved fed-state performance, lower dose variability, reduced capsule burden, pediatric and hypogonadal-use adaptations, international formulations, and generic or authorized-generic development. The main barriers are testosterone’s narrow therapeutic window, monitoring requirements, androgen-class safety concerns, formulation similarity, and potentially strong formulation and method-of-use patent protection.

What is JATENZO and how does its formulation work?

JATENZO is an oral testosterone undecanoate capsule approved by the U.S. Food and Drug Administration in 2019 for testosterone replacement therapy in adult men with conditions associated with a deficiency or absence of endogenous testosterone. It is marketed as a prescription softgel capsule and is administered twice daily with food.[1]

Testosterone undecanoate is a lipophilic testosterone ester. Oral delivery requires protection from extensive first-pass metabolism and adequate intestinal absorption. JATENZO uses a lipid-based formulation to improve solubilization and transport through the gastrointestinal tract. Dietary fat can materially affect absorption, which explains the product’s food-administration requirement.

The labeled strength is 237 mg of testosterone undecanoate per capsule. The starting dose is generally two capsules in the morning, with subsequent dose adjustment based on serum testosterone concentrations. The label permits a total daily dose of three to four capsules, depending on the patient’s response and measured testosterone level.[1]

What inactive ingredients are used in JATENZO?

The public prescribing information identifies excipients associated with the capsule shell and fill formulation. Publicly disclosed inactive ingredients include lipid vehicles and capsule-shell components such as medium-chain triglycerides, oleic acid-related lipid materials, gelatin, glycerin, titanium dioxide, and coloring agents. The exact quantitative formulation, manufacturing sequence, particle-size controls, and process parameters are not fully disclosed in the prescribing information.[1]

For commercial development, the relevant excipient categories are:

Excipient category	Formulation function	Commercial significance
Medium-chain triglycerides or related lipid vehicles	Solubilize testosterone undecanoate and promote intestinal dispersion	Directly affects exposure, food effect, and capsule fill volume
Long-chain or unsaturated fatty materials	Support lipid digestion and drug partitioning	Can improve absorption but may increase oxidation and stability risks
Surfactant or self-emulsifying components	Promote fine dispersion in gastrointestinal fluid	May reduce dose variability and capsule size
Gelatin	Forms the softgel shell	Controls oxygen and moisture permeability, dissolution, and patient acceptability
Glycerin or related plasticizer	Maintains shell flexibility	Influences shell brittleness and long-term stability
Titanium dioxide and colorants	Provide opacity and product identification	Affect regulatory acceptability and global formulation portability

A generic developer would need to characterize the complete reference-product formulation analytically rather than rely only on the label. Critical targets would include drug loading, lipid composition, fill viscosity, shell composition, dissolution under fed and fasted conditions, degradation products, and testosterone exposure.

How does JATENZO’s excipient strategy create commercial value?

The core commercial value is oral delivery without daily transdermal application or periodic injection. The formulation must deliver sufficient testosterone while limiting intra-patient variability and avoiding excessive dependence on a high-fat meal.

Food-effect control

JATENZO must be taken with food. The label specifies administration with meals, and food composition can influence lipid digestion, solubilization, and systemic exposure.[1] A follow-on formulation that produces more consistent exposure across ordinary meals could support a differentiated product.

Potential development targets include:

• Reduced sensitivity to meal fat content
• Reliable absorption with a standard meal
• Lower variability between morning and evening dosing
• Improved exposure after low-fat meals
• Fewer dose titrations
• Reduced risk of supraphysiologic testosterone concentrations

A formulation with a less pronounced food effect could have value in markets where patients have inconsistent meal patterns or where adherence to meal instructions is poor.

Capsule burden

The approved regimen may require three or four capsules per day after titration. A higher-strength capsule, more concentrated fill, or more efficient self-emulsifying system could reduce the daily capsule count.

This opportunity must be balanced against:

• Increased fill viscosity
• Larger capsule dimensions
• Greater risk of incomplete dispersion
• Higher drug load per unit
• More difficult softgel manufacturing
• Increased exposure variability if the formulation is overly efficient

A two-capsule daily regimen would provide a clear commercial message, but achieving it without increasing peak testosterone levels would be technically difficult.

Patient acceptability

Softgel capsules avoid several disadvantages associated with testosterone gels and patches, including transfer risk, skin irritation, visible application sites, and daily topical handling. Compared with injections, oral administration avoids injection-site discomfort and clinic administration.

Excipient choices can support patient acceptability through:

• Smaller capsules
• Neutral odor and taste
• Improved swallowing characteristics
• Lower shell tackiness
• Better stability in hot and humid climates
• Avoidance of excipients associated with dietary, religious, or allergy restrictions

What formulations are protected by JATENZO-related patents?

JATENZO’s intellectual-property position is expected to center on more than the testosterone undecanoate molecule. The potentially relevant claim categories include:

1. Oral testosterone undecanoate formulations containing specific lipid vehicles.
2. Self-emulsifying or lipid-based delivery systems.
3. Dose-escalation and serum-testosterone monitoring methods.
4. Administration with food or defined meal conditions.
5. Capsule compositions and fill ratios.
6. Methods for treating hypogonadal men with oral testosterone undecanoate.
7. Pharmacokinetic limitations relating to testosterone or dihydrotestosterone exposure.
8. Manufacturing processes for softgel filling and encapsulation.

The active ingredient itself is old and cannot provide meaningful standalone composition-of-matter protection. Commercial protection therefore depends on formulation claims, method-of-use claims, regulatory exclusivity, trade secrets, and the practical difficulty of demonstrating pharmaceutical equivalence.

Public patent databases identify Clarus Therapeutics and related entities as important developers of oral testosterone undecanoate technology. Patent expiration dates must be reviewed patent by patent because terminal disclaimers, patent-term adjustment, continuations, and later-issued formulation patents can create different endpoints.

What is the FDA regulatory status of JATENZO?

The FDA approved JATENZO in March 2019 under the 505(b)(2) pathway.[2] The product was approved for testosterone replacement in adult males with hypogonadism associated with medical conditions, rather than for general age-related declines in testosterone.

The regulatory profile includes several constraints:

• Testosterone is a controlled substance in the United States.
• JATENZO requires monitoring of testosterone concentrations.
• The product carries warnings concerning blood pressure increases and cardiovascular risk considerations.
• Testosterone therapy can affect hematocrit, prostate-related parameters, lipids, fertility, and sleep apnea.
• The label requires dose adjustment based on serum testosterone testing.
• Long-term clinical use is constrained by the need for appropriate diagnosis and ongoing monitoring.

The FDA has required postmarketing evaluation of blood pressure effects for testosterone products. JATENZO’s label includes blood-pressure-related warnings that may affect prescriber choice and payer positioning.[1]

How does JATENZO compare with other testosterone products?

Product type	Primary excipient or delivery issue	Main commercial advantage	Main limitation
JATENZO oral softgel	Lipid-based absorption and food effect	No injection or topical transfer risk	Multiple daily capsules and food-dependent dosing
Testosterone cypionate injection	Oil depot vehicle	Infrequent dosing and established generic supply	Injection burden and peak-trough fluctuations
Testosterone enanthate injection	Oil depot vehicle	Broad physician familiarity	Injection-related adherence problems
Transdermal gel	Alcohol or hydroalcoholic vehicle	Flexible daily dosing	Transfer risk and skin application
Transdermal patch	Adhesive and permeation system	Continuous delivery	Skin irritation and adhesion problems
Buccal testosterone	Mucoadhesive excipients	Avoids injections and gastrointestinal swallowing	Local irritation and administration complexity
Other oral testosterone products	Lipid or modified-release technology	Oral convenience	Absorption, hepatic, and exposure concerns

JATENZO competes most directly with injectable testosterone on convenience and with topical products on avoidance of transfer. It is less advantaged on dosing simplicity than long-acting injections and less advantaged on predictable absorption than some transdermal products.

What commercial opportunities exist for JATENZO excipient innovation?

Lower-food-effect oral testosterone

The strongest formulation opportunity is a product that maintains therapeutic exposure with ordinary meals. This could be pursued through a self-emulsifying drug-delivery system, a redesigned lipid blend, a supersaturating formulation, or a formulation containing digestion-resistant solubilizers.

A successful product would need clinical evidence showing that the improved absorption profile does not create excessive peak concentrations or increase adverse-event risk.

Higher-strength or reduced-frequency dosing

A more concentrated fill could reduce capsule burden. A once-daily product would have substantial commercial value but would require a pharmacokinetic profile that avoids high morning peaks and late-day troughs.

Dose-frequency claims may be patentable if linked to specific formulations, exposure parameters, or monitoring methods.

Pediatric and adolescent formulations

Testosterone replacement in adolescents and young adults can involve gradual dose escalation. A lower-strength softgel or sprinkle-compatible formulation could support more precise titration, although pediatric development would involve separate safety, dosing, and regulatory requirements.

Potential formats include:

• Lower-strength softgels
• Oral liquid lipid systems
• Unit-dose sachets
• Capsules that can be administered with food vehicles
• Multiparticulate systems with controlled release

Taste masking and dose uniformity would become more important in pediatric products.

Global excipient redesign

Some U.S. excipients may face restrictions or market-specific acceptance issues. International commercialization may require alternatives to:

• Titanium dioxide
• Certain colorants
• Animal-derived gelatin
• Specific surfactants
• Oxidation-sensitive oils

A vegetarian or non-animal capsule shell could expand access in selected markets. Hydroxypropyl methylcellulose and other non-gelatin shell systems may improve geographic portability, but they can change oxygen permeability, dissolution, sealing, and stability.

Authorized generic or licensed follow-on product

A lower-cost version could target payers and health systems that resist branded oral testosterone pricing. A licensed follow-on strategy would reduce commercial development risk but would require agreement on manufacturing, supply, brand use, and litigation exposure.

The formulation’s lipid system is likely to be the principal technical barrier. A generic applicant must demonstrate sameness or equivalence without reproducing undisclosed process know-how.

What manufacturing and intellectual-property barriers affect generic entry?

Softgel manufacturing creates several barriers that are less visible than the active ingredient:

• Uniform dispersion of a high-dose lipophilic ester
• Control of fill viscosity during encapsulation
• Prevention of leakage and shell brittleness
• Control of peroxide formation in lipid excipients
• Protection from oxygen, heat, and light
• Consistent dissolution after long-term storage
• Control of capsule weight variation
• Reproducibility of fed-state pharmacokinetics

These manufacturing attributes may be protected by process patents or retained as trade secrets. Even where a patent challenge succeeds, a generic applicant may need substantial development work to match the reference product’s in vivo performance.

Are Paragraph IV challenges and generic launches likely?

A Paragraph IV applicant could challenge formulation, method-of-use, or regulatory patents listed for JATENZO in the FDA Orange Book. The most plausible arguments would target:

• Lack of novelty in lipid-based oral testosterone delivery
• Obviousness based on earlier testosterone undecanoate and self-emulsifying formulations
• Insufficient written description for broad excipient claims
• Lack of enablement for wide formulation ranges
• Non-infringement based on a different lipid system
• Invalidity of narrow food-effect or pharmacokinetic limitations

A generic launch could occur through several pathways:

Launch scenario	Commercial timing	Risk profile
At-risk launch after Paragraph IV certification	Before all patent expiry dates	High damages and injunction exposure
Launch after settlement license date	Contract-defined	Depends on settlement restrictions
Launch after patent expiry	Later but lower litigation risk	Requires market preparation
Authorized generic	Controlled by brand owner or licensee	Lower legal risk but dependent on agreement
505(b)(2) reformulation	Potentially earlier differentiation	Requires clinical or bridging evidence

No public litigation or settlement conclusion should be inferred solely from the existence of a Paragraph IV filing. Patent status, court outcomes, and settlement terms must be reviewed against current FDA listings and federal court records.

What licensing deals and companies affect JATENZO’s commercial position?

Clarus Therapeutics developed JATENZO and built the product’s original commercial infrastructure. The company’s financial and operational history has affected product availability, commercialization capacity, and potential licensing structures.

Relevant counterparties can include:

• The original innovator and its successor commercial entities
• Softgel contract manufacturers
• Testosterone API suppliers
• Specialty-pharmacy distributors
• Men’s-health telehealth platforms
• Urology and endocrinology-focused commercial partners
• Generic manufacturers with lipid-based softgel capability

A licensing deal would be most valuable if it combines U.S. commercial rights with manufacturing scale and regulatory support. A regional license may be attractive where testosterone replacement markets are large but local formulation requirements differ.

How strong is the JATENZO patent estate?

The estate is stronger when evaluated as a formulation-and-regulatory package rather than as a molecule patent. Its practical strength depends on four factors:

1. Whether broad lipid-formulation claims survive validity challenges.
2. Whether the formulation claims cover commercially viable design-around products.
3. Whether method-of-use claims can be enforced against generic labeling.
4. Whether manufacturing know-how remains difficult to replicate.

The estate is weaker against a generic that uses a materially different excipient system and avoids patented food-effect or dosing limitations. It is stronger if the FDA-approved product characteristics are tied to narrow but commercially necessary pharmacokinetic parameters.

What revenue exposure does JATENZO create?

Revenue exposure depends on prescription volume, payer coverage, net price, and the share of patients switching from injections or topical products. The product’s addressable population is adult men with confirmed hypogonadism who require testosterone replacement and prefer oral treatment.

Commercial constraints include:

• Prior authorization
• Diagnosis and laboratory documentation
• Controlled-substance handling
• Blood-pressure monitoring
• Serum testosterone titration
• Competition from low-cost injectable generics
• Limited differentiation among testosterone products

The most valuable commercial segment is likely patients who discontinue injections because of administration burden or avoid gels because of transfer and skin concerns. A lower-food-effect, lower-pill-burden formulation could expand this segment.

Key Takeaways

• JATENZO’s principal formulation asset is its lipid-based oral delivery of testosterone undecanoate.
• Excipients control solubilization, food effect, exposure variability, capsule burden, and stability.
• The strongest commercial opportunity is a formulation with more predictable absorption under ordinary meals.
• Reduced capsule count, lower-strength pediatric units, and non-gelatin global versions are viable follow-on concepts.
• Generic entry is constrained by formulation equivalence, softgel manufacturing, pharmacokinetic variability, and formulation or method-of-use patents.
• JATENZO’s molecule is not the main source of exclusivity. Commercial protection rests on formulation patents, regulatory exclusivity, process know-how, and brand positioning.
• The product competes with inexpensive testosterone injections as well as topical gels, patches, and buccal systems.
• Regulatory monitoring, blood-pressure concerns, and controlled-substance requirements limit rapid market expansion.

FAQs

Can JATENZO be reformulated without changing its FDA approval?

A material change to the lipid vehicle, capsule shell, dose, absorption profile, or administration instructions could require a supplemental application, a new 505(b)(2) application, or a generic-equivalence pathway, depending on the development strategy.

Which excipient is most important for JATENZO absorption?

The lipid vehicle system is the critical excipient group because it controls testosterone undecanoate solubilization, digestion, intestinal dispersion, and food-dependent exposure. No single excipient should be evaluated independently from the complete lipid composition.

Could a once-daily JATENZO formulation be commercially viable?

Yes, but it would require a pharmacokinetic profile that maintains therapeutic testosterone levels without excessive peak exposure. A once-daily formulation could command a meaningful adherence advantage if supported by clinical data and protected by differentiated formulation claims.

Does JATENZO have biosimilar risk?

No. JATENZO contains a chemically synthesized small-molecule testosterone ester, not a biologic. Its relevant competitive risk is generic, authorized-generic, 505(b)(2), or reformulated oral testosterone competition.

What is the main design-around strategy for a JATENZO generic?

The most credible design-around strategy is a different lipid or self-emulsifying system that achieves comparable exposure while avoiding specific excipient, ratio, process, or pharmacokinetic limitations in asserted patents.

References

1. U.S. Food and Drug Administration. (2023). JATENZO (testosterone undecanoate) capsules, prescribing information. Clarus Therapeutics, LLC.

2. U.S. Food and Drug Administration. (2019, March 27). FDA approves new oral testosterone capsule for certain men with hypogonadism. FDA.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2023). Testosterone products: Drug safety communication and labeling information. FDA.

5. U.S. Patent and Trademark Office. (n.d.). Patent records relating to oral testosterone undecanoate formulations and methods of use. Patent Center.